questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Phosphotransferases
Phosphotransferases (Phosphate Group Acceptor)
Phosphotransferases (Phosphate Group Acceptor) : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases (Phosphate Group Acceptor) : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases (Phosphate Group Acceptor) : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases (Phosphate Group Acceptor) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-31",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphotransferases",
"url": "https://questionsmedicales.fr/mesh/D010770",
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases",
"code": {
"@type": "MedicalCode",
"code": "D010770",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adenylate kinase",
"alternateName": "Adenylate Kinase",
"url": "https://questionsmedicales.fr/mesh/D000263",
"about": {
"@type": "MedicalCondition",
"name": "Adenylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D000263",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "ATP synthetase complexes",
"alternateName": "ATP Synthetase Complexes",
"url": "https://questionsmedicales.fr/mesh/D025181",
"about": {
"@type": "MedicalCondition",
"name": "ATP synthetase complexes",
"code": {
"@type": "MedicalCode",
"code": "D025181",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Guanylate kinase",
"alternateName": "Guanylate Kinases",
"url": "https://questionsmedicales.fr/mesh/D051528",
"about": {
"@type": "MedicalCondition",
"name": "Guanylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D051528",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside diphosphate kinase",
"alternateName": "Nucleoside-Diphosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009701",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside diphosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009701",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NM23 Nucleoside Diphosphate kinases",
"alternateName": "NM23 Nucleoside Diphosphate Kinases",
"url": "https://questionsmedicales.fr/mesh/D054778",
"about": {
"@type": "MedicalCondition",
"name": "NM23 Nucleoside Diphosphate kinases",
"code": {
"@type": "MedicalCode",
"code": "D054778",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside phosphate kinase",
"alternateName": "Nucleoside-Phosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009703",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside phosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009703",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.575"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"alternateName": "Phosphotransferases (Phosphate Group Acceptor)",
"code": {
"@type": "MedicalCode",
"code": "D017856",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch."
}
},
{
"@type": "Person",
"name": "Zengqi Xie",
"url": "https://questionsmedicales.fr/author/Zengqi%20Xie",
"affiliation": {
"@type": "Organization",
"name": "Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China."
}
},
{
"@type": "Person",
"name": "Bernhard Erni",
"url": "https://questionsmedicales.fr/author/Bernhard%20Erni",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Yulin Zhu",
"url": "https://questionsmedicales.fr/author/Yulin%20Zhu",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
},
{
"@type": "Person",
"name": "Feng He",
"url": "https://questionsmedicales.fr/author/Feng%20He",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "HMOX1 genetic polymorphisms and outcomes in infectious disease: A systematic review.",
"datePublished": "2022-05-12",
"url": "https://questionsmedicales.fr/article/35551540",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0267399"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetic polymorphism of Y-chromosome in Kazakh populations from Southern Kazakhstan.",
"datePublished": "2023-10-27",
"url": "https://questionsmedicales.fr/article/37891458",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12864-023-09753-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tardive Dyskinesia Development, Superoxide Dismutase Levels, and Relevant Genetic Polymorphisms.",
"datePublished": "2022-10-28",
"url": "https://questionsmedicales.fr/article/36338339",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/5748924"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Analysis of Genetic Polymorphism on Mitochondrial Hypervariable Region III in Thai Population.",
"datePublished": "2023-03-09",
"url": "https://questionsmedicales.fr/article/36980954",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes14030682"
}
},
{
"@type": "ScholarlyArticle",
"name": "Investigating genetic polymorphism in E. histolytica isolates with distinct clinical phenotypes.",
"datePublished": "2023-08-29",
"url": "https://questionsmedicales.fr/article/37642770",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00436-023-07952-x"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphotransferases",
"item": "https://questionsmedicales.fr/mesh/D010770"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"item": "https://questionsmedicales.fr/mesh/D017856"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases (Phosphate Group Acceptor) - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Comment diagnostiquer une déficience en phosphotransférases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphotransférases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nPeut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Polymorphism,+Genetic&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les symptômes d'une déficience en phosphotransférases ?\nLes troubles neurologiques sont-ils liés aux phosphotransférases ?\nComment les symptômes varient-ils selon le type d'enzyme ?\nLes symptômes apparaissent-ils à la naissance ?\nY a-t-il des symptômes spécifiques aux enfants ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Polymorphism,+Genetic&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Peut-on prévenir les déficiences en phosphotransférases ?\nLes tests de dépistage néonatal sont-ils utiles ?\nY a-t-il des recommandations diététiques préventives ?\nLes conseils génétiques sont-ils importants ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Polymorphism,+Genetic&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à traiter ces déficiences ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la gestion diététique aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Polymorphism,+Genetic&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes troubles cardiaques sont-ils une complication possible ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Polymorphism,+Genetic&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les facteurs de risque pour ces déficiences ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'alimentation peut-elle influencer le risque ?\nLes infections peuvent-elles aggraver la condition ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Polymorphism,+Genetic&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphotransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour évaluer l'activité des phosphotransférases."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphotransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de dosage enzymatique et les analyses de métabolites sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes métaboliques, comme la fatigue ou des troubles énergétiques, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les phosphotransférases."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphotransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, faiblesse musculaire, troubles de la croissance et anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux phosphotransférases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent de l'enzyme spécifique affectée et de son rôle métabolique."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils à la naissance ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent apparaître à la naissance, tandis que d'autres se développent plus tard."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux enfants ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent présenter des retards de développement et des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en phosphotransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage néonatal sont-ils utiles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage néonatal peuvent identifier certaines déficiences précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques préventives ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recommandations diététiques peuvent être établies pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les déficiences, mais protègent contre les infections."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments nutritionnels et une gestion diététique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces déficiences."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à traiter ces déficiences ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à gérer les symptômes, mais ne corrigent pas la déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études cliniques explorent de nouvelles approches thérapeutiques pour ces conditions."
}
},
{
"@type": "Question",
"name": "Comment la gestion diététique aide-t-elle ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion diététique peut aider à compenser les déficiences métaboliques et à améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces déficiences ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques, neurologiques et de croissance peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les troubles cardiaques sont-ils une complication possible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cardiaques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies métaboliques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des déficiences en phosphotransférases peuvent avoir un risque accru de maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour ces déficiences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies auto-immunes peuvent affecter le métabolisme et augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée peut exacerber les symptômes chez les personnes à risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la condition ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher ou aggraver les symptômes liés aux déficiences enzymatiques."
}
}
]
}
]
}
Heme-oxygenase 1 (HMOX1) is a critical stress response gene that catalyzes the multistep oxidation of heme. A GT(n) repeat of variable length in the promoter in has been associated with a wide range o...
A search using relevant terms was performed in PubMED and EMBASE through to 15/01/21 identifying all research that studied an association between the HMOX1 GT(n) repeat polymorphism and the incidence ...
1,533 studies were identified in the search, and one via citation screening. Sixteen studies were ultimately included, seven in malaria, three in HIV, three in sepsis, and one each in pneumonia, hepat...
Despite the importance of HMOX1 in survival from infection, and the association between repeat length and gene expression, the clinical data supporting an association between repeat length and inciden...
The Kazakhs are one of the biggest Turkic-speaking ethnic groups, controlling vast swaths of land from the Altai to the Caspian Sea. In terms of area, Kazakhstan is ranked ninth in the world. Northern...
The Kazakhstan Y-chromosome Haplotype Reference Database was expanded with 468 Kazakh males from the Zhambyl and Turkestan regions of South Kazakhstan by having their 27 Y-STR loci and 23 Y-SNP marker...
The Kazakhstan Y-chromosome Haplotype Reference Database was formed for 27 Y-STR loci with a total sample of 1796 samples of Kazakhs from 16 regions of Kazakhstan. The variability of the Y-chromosome ...
Tardive dyskinesia (TD) is a prevalent movement disorder that significantly impacts patients with schizophrenia (SCZ) due to extended exposure to antipsychotics (AP). Several genetic polymorphisms, in...
Mitochondrial DNA (mtDNA) analysis is a genetic marker for human identification, especially matrilineal inheritance. Hypervariable regions (HVR) I and II of mtDNA have been currently performed for hum...
Amoebiasis is an infection caused by enteric protozoa, most commonly Entamoeba histolytica, and is globally considered a potentially severe and life-threatening condition. To understand the impact of ...
Occupational exposure to toluene causes serious health problems ranging from drowsiness to lethal diseases such as cancer. Paint workers are exposed to toluene through inhalation or the dermal route, ...
First, we included skilled paint workers (n = 30) as exposed and healthy individuals (n = 30) as control belonging to the same socio-economic strata. The genotoxicity biomarkers, Cytokinesis-block mic...
A significantly higher frequency of CBMN (4.43 ± 1.50) and tail moment (TM) (11.23 ± 1.0) respectively in paint workers as compared to the control(1.50 ± 0.86 and (0.54 ± 0.37) underlined significantl...
Overall, our study provides a strong rationale for identifying a clear association between glutathione-S-transferase polymorphism and genetic damage in paint workers....
To identify, critically evaluate and synthesize the evidence obtained from systematic reviews on the association between genetic polymorphisms and osteoarthritis (OA) development....
Considering gene polymorphisms associated with OA susceptibility (risk or protection), a comprehensive search was conducted in the following databases, without date or language restrictions: MEDLINE, ...
We included 14 systematic reviews of case-control studies comparing individuals with a radiographic diagnosis of all OA types and healthy controls, all submitted to the genetic examination of differen...
Based on low-quality to critically-low-quality systematic reviews, some gene polymorphisms seem to be associated with risk or protection for OA. Further high-quality studies are needed to validate the...
Tolperisone, a muscle relaxant used for post-stroke spasticity, is metabolized to its main metabolite by CYP2D6 and to a lesser extent by CYP2C19 and CYP1A2. We investigated the effects of CYP2D6 and ...
Silicosis is a pneumoconiosis characterized by fibrosis of the lung parenchyma caused by inhalation of silica particles. Genetic factors might play a role in the severity silicosis. We sought to evalu...
Nine polymorphisms were genotyped by PCR in a sample of 143 patients with silicosis in the state of Rio de Janeiro, Brazil....
Fifty-seven patients (40%) were classified as having simple silicosis and 86 (60%) were classified as having complicated silicosis. The TT genotype of rs1800469 in the TGFB1 gene showed a protective e...
It appears that rs1800469 polymorphisms in the TGFB1 gene and rs763110 polymorphisms in the FASLG gene are involved in the severity of silicosis. Given the lack of studies relating genetic polymorphis...
Many pharmacokinetic studies of lacosamide (LCM) have been reported, but no large-scale clinical study has been conducted on genetic polymorphisms that affect the metabolism of LCM. Therefore, we desi...
Adult patients with epilepsy who received LCM at Seoul National University Hospital were enrolled. Blood samples were obtained from 115 patients taking LCM for more than 1 month with unchanged doses a...
The serum LCM concentration showed a linear correlation with the daily dose (r = .66, p < .001). In genetic analysis, 43 patients (38.7%) were extensive metabolizers (EMs), 51 (45.9%) were intermediat...
Genetic polymorphisms of the CYP2C19 gene affect the serum LCM concentration. Because efficacy and toxicity are apparently related to serum LCM levels, the genetic phenotype of CYP2C19 should be consi...